FI954773A7 - Antihypertriglyserideeminen koostumus - Google Patents

Antihypertriglyserideeminen koostumus Download PDF

Info

Publication number
FI954773A7
FI954773A7 FI954773A FI954773A FI954773A7 FI 954773 A7 FI954773 A7 FI 954773A7 FI 954773 A FI954773 A FI 954773A FI 954773 A FI954773 A FI 954773A FI 954773 A7 FI954773 A7 FI 954773A7
Authority
FI
Finland
Prior art keywords
antihypertriglyceridemic
composition
antihypertriglyceridemic composition
Prior art date
Application number
FI954773A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI954773A0 (fi
Inventor
Yasuo Sugiyama
Hidefumi Yukimasa
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of FI954773A0 publication Critical patent/FI954773A0/fi
Publication of FI954773A7 publication Critical patent/FI954773A7/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
FI954773A 1994-10-07 1995-10-06 Antihypertriglyserideeminen koostumus FI954773A7 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP24413694 1994-10-07

Publications (2)

Publication Number Publication Date
FI954773A0 FI954773A0 (fi) 1995-10-06
FI954773A7 true FI954773A7 (fi) 1996-04-08

Family

ID=17114301

Family Applications (1)

Application Number Title Priority Date Filing Date
FI954773A FI954773A7 (fi) 1994-10-07 1995-10-06 Antihypertriglyserideeminen koostumus

Country Status (11)

Country Link
EP (1) EP0705607A2 (cg-RX-API-DMAC10.html)
KR (1) KR960013370A (cg-RX-API-DMAC10.html)
CN (1) CN1128657A (cg-RX-API-DMAC10.html)
AU (1) AU703422B2 (cg-RX-API-DMAC10.html)
CA (1) CA2160092A1 (cg-RX-API-DMAC10.html)
FI (1) FI954773A7 (cg-RX-API-DMAC10.html)
HU (1) HUT73422A (cg-RX-API-DMAC10.html)
NO (1) NO308580B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ280165A (cg-RX-API-DMAC10.html)
RU (1) RU2166320C2 (cg-RX-API-DMAC10.html)
TW (1) TW401301B (cg-RX-API-DMAC10.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1072649C (zh) * 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
PT862562E (pt) * 1995-09-13 2001-11-30 Takeda Chemical Industries Ltd Compostos de benzoxazepina sua producao e utilizacao como agentes para reducao dos niveis de lipidos
EP0843559A2 (en) * 1996-06-11 1998-05-27 Zonagen, Inc. Chitosan drug delivery system
CN1252795A (zh) 1997-04-21 2000-05-10 武田药品工业株式会社 4,1-苯并氧氮杂、它们的类似物和它们作为抑生长素兴奋剂的用途
JP4204657B2 (ja) * 1997-12-05 2009-01-07 有限会社ケムフィズ 糖尿病の予防・治療剤
KR100584650B1 (ko) 1998-03-31 2006-05-30 디 인스티튜트스 포 파마슈티컬 디스커버리, 엘엘씨 치환된 인돌알칸산
US6207664B1 (en) 1998-11-25 2001-03-27 Pfizer Inc. Squalene synthetase inhibitor agents
TNSN99224A1 (fr) * 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
AU5588400A (en) 1999-05-26 2000-12-18 Du Pont Pharmaceuticals Company 1,4-benzodiazepin-2-ones useful as hiv reverse transcriptase inhibitors
EP1210338A2 (en) * 1999-08-05 2002-06-05 IGT Pharma Inc. 1,4-diazepine derivatives for the treatment of diseases related to the central nervous system
KR20030048465A (ko) * 2000-11-09 2003-06-19 다케다 야쿠힌 고교 가부시키가이샤 고밀도 지질단백질-콜레스테롤 상승제
EP1365745A2 (en) 2001-02-15 2003-12-03 King Pharmaceuticals, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
US20030027786A1 (en) * 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
EP1407782A4 (en) * 2001-06-28 2004-10-20 Takeda Chemical Industries Ltd AGENTS FOR PREVENTION / TREATMENT OF FUNCTIONAL ORGANIC DISEASES AND ORGANIC DYSFUNCTION
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
CA2514547A1 (en) 2003-01-28 2004-08-12 Takeda Pharmaceutical Company Limited Receptor agonists
CA2546601A1 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
JP2008509074A (ja) * 2004-08-09 2008-03-27 武田薬品工業株式会社 Crp低下剤
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
RU2008119687A (ru) 2005-10-21 2009-11-27 Новартис АГ (CH) Комбинации органических соединений
BRPI0811204A8 (pt) 2007-05-10 2015-09-22 Bristol Myers Squibb Co Tetra-hidroibenzo-1,4-diazepinas substituídas por arila e heteroarila e uso das mesmas para bloquear a recaptação de norepinefrina, dopamina e serotonina
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
KR20240131463A (ko) 2020-05-05 2024-08-30 뉴베일런트, 아이엔씨. 헤테로방향족 거대환식 에터 화학치료제
JP7519463B2 (ja) 2020-05-05 2024-07-19 ヌバレント, インク. ヘテロ芳香族大環状エーテル化学療法剤
CN118234725A (zh) 2021-10-01 2024-06-21 纽威伦特公司 杂芳族大环醚化合物的固体形式、药物组合物及制备

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180717A (en) * 1988-08-16 1993-01-19 The Upjohn Company Bivalent ligands effective for blocking ACAT enzyme for lowering plasma triglycerides and for elevating HDL cholesterol
FR2659332B1 (fr) * 1990-03-08 1994-04-29 Adit Et Cie Nouvelles pyrrolo [1,2-a] thieno [3,2-f] diazepines [1,4], leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
DE69332792T2 (de) * 1992-04-20 2004-01-15 Takeda Chemical Industries Ltd 4,1-Benzoxazepinderivate als Squalen-Synthetase Inhibitoren und ihre Verwendung zur Behandlung von Hypercholesterämie und als Fungizide
CA2099346A1 (en) * 1992-07-17 1994-01-18 Shinji Ohmori Lipid metabolism improving composition
AU678503B2 (en) * 1993-09-24 1997-05-29 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds and their use as squalene synthetase inhibitors
WO1995021834A1 (en) * 1994-02-09 1995-08-17 Takeda Chemical Industries, Ltd. Optically active 4,1-benzoxazepine derivatives useful as squalene synthase inhibitors

Also Published As

Publication number Publication date
NO953961D0 (no) 1995-10-05
TW401301B (en) 2000-08-11
KR960013370A (ko) 1996-05-22
EP0705607A3 (cg-RX-API-DMAC10.html) 1996-05-08
EP0705607A2 (en) 1996-04-10
CA2160092A1 (en) 1996-04-08
NO308580B1 (no) 2000-10-02
NO953961L (no) 1996-04-09
FI954773A0 (fi) 1995-10-06
AU3308195A (en) 1996-04-18
RU2166320C2 (ru) 2001-05-10
AU703422B2 (en) 1999-03-25
CN1128657A (zh) 1996-08-14
HU9502918D0 (en) 1995-11-28
NZ280165A (en) 1997-07-27
HUT73422A (en) 1996-07-29

Similar Documents

Publication Publication Date Title
DE69526966D1 (de) Hautkräftigende kometische zusammensetzung
DE69718508D1 (de) Antitraspirant zusammensetzung
DE69516018D1 (de) Verdickte persäurezusammensetzungen
FI954008A7 (fi) Substituoituja bifenyyli-isoksatsolisulfoniamideja
FI951908L (fi) Substituoituja pyridyylipyratsoleja
FI955927L (fi) Substituoidut 1H-imidatsolit
NO985460D0 (no) Limsammensetning
BR9508318A (pt) Composição impadora concentrada
DE69534718D1 (de) Substituierte 9-alkyladenine
FI954773A7 (fi) Antihypertriglyserideeminen koostumus
ID18359A (id) Komposisi mikrokapsul
BR9606809A (pt) Composição inseticidamente ativa
FI942119A0 (fi) Anordning i en gasblandare
BR9607058A (pt) Composição
PT728814E (pt) Composicao betuminosa
ID19589A (id) Komposisi
BR9609903A (pt) ComposiçÃo inseticidamente ativa
ITMI940362A0 (it) Composizione antitosse
BR9707835A (pt) Composiç
BR9509899A (pt) Composição modificadora de sabor
DE69616374D1 (de) Germizide zusammensetzung
MA23731A1 (fr) Compositions detegentes
BR9709815A (pt) Composicão
BR9607946A (pt) Composição
KR950033309U (ko) 줄연장